Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19961893rdf:typepubmed:Citationlld:pubmed
pubmed-article:19961893lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:19961893lifeskim:mentionsumls-concept:C0295352lld:lifeskim
pubmed-article:19961893lifeskim:mentionsumls-concept:C0001563lld:lifeskim
pubmed-article:19961893lifeskim:mentionsumls-concept:C1314792lld:lifeskim
pubmed-article:19961893lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:19961893lifeskim:mentionsumls-concept:C1314939lld:lifeskim
pubmed-article:19961893lifeskim:mentionsumls-concept:C0332120lld:lifeskim
pubmed-article:19961893pubmed:issue2lld:pubmed
pubmed-article:19961893pubmed:dateCreated2010-2-22lld:pubmed
pubmed-article:19961893pubmed:abstractTextThe present study investigated a possible antidepressant-like activity of bis selenide using two predictive tests for antidepressant effect on rodents: the forced swimming test (FST) and the tail suspension test (TST). Bis selenide (0.5-5 mg/kg, p.o.) decreased the immobility time in the mouse FST and TST. The anti-immobility effect of bis selenide (1 mg/kg, p.o.) in the TST was prevented by the pretreatment of mice with p-chlorophenylalanine methyl ester (PCPA; 100 mg/kg, i.p., an inhibitor of serotonin synthesis), ketanserin (1 mg/kg, i.p., a 5-HT(2A/2C) receptor antagonist), and ondasentron (1 mg/kg, i.p., a 5-HT(3) receptor antagonist). Pretreatment of mice with prazosin (1 mg/kg, i.p., an alpha(1)-adrenoceptor antagonist), yohimbine (1 mg/kg, i.p., an alpha(2)-adrenoceptor antagonist), propranolol (2 mg/kg, i.p., a beta-adrenoceptor antagonist), SCH23390 (0.05 mg/kg, s.c., a dopamine D(1) receptor antagonist), sulpiride (50 mg/kg, i.p., a dopamine D(2) receptor antagonist), or WAY 100635 (0.1 mg/kg, s.c., a selective 5-HT(1A) receptor antagonist) did not block the antidepressant-like effect of bis selenide (1 mg/kg, p.o.) in the TST. Administration of bis selenide (0.1 mg/kg, p.o.) and fluoxetine (1 mg/kg), at subeffective doses, produced an antidepressant-like effect in the TST. Bis selenide did not alter Na(+) K(+) ATPase, MAO-A and MAO-B activities in whole brains of mice. Bis selenide produced an antidepressant-like effect in the mouse TST and FST, which may be related to the serotonergic system (5-HT(2A/2C) and 5-HT(3) receptors).lld:pubmed
pubmed-article:19961893pubmed:languageenglld:pubmed
pubmed-article:19961893pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:citationSubsetIMlld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19961893pubmed:statusMEDLINElld:pubmed
pubmed-article:19961893pubmed:monthMarlld:pubmed
pubmed-article:19961893pubmed:issn1878-4216lld:pubmed
pubmed-article:19961893pubmed:authorpubmed-author:NogueiraCrist...lld:pubmed
pubmed-article:19961893pubmed:authorpubmed-author:JesseCristian...lld:pubmed
pubmed-article:19961893pubmed:authorpubmed-author:WilhelmEthel...lld:pubmed
pubmed-article:19961893pubmed:authorpubmed-author:BortolattoCri...lld:pubmed
pubmed-article:19961893pubmed:copyrightInfoCopyright 2009 Elsevier Inc. All rights reserved.lld:pubmed
pubmed-article:19961893pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19961893pubmed:day17lld:pubmed
pubmed-article:19961893pubmed:volume34lld:pubmed
pubmed-article:19961893pubmed:ownerNLMlld:pubmed
pubmed-article:19961893pubmed:authorsCompleteYlld:pubmed
pubmed-article:19961893pubmed:pagination294-302lld:pubmed
pubmed-article:19961893pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:meshHeadingpubmed-meshheading:19961893...lld:pubmed
pubmed-article:19961893pubmed:year2010lld:pubmed
pubmed-article:19961893pubmed:articleTitleEvidence for the involvement of the serotonergic 5-HT2A/C and 5-HT3 receptors in the antidepressant-like effect caused by oral administration of bis selenide in mice.lld:pubmed
pubmed-article:19961893pubmed:affiliationLaboratório de Síntese, Reatividade e Avaliação Farmacológica e Toxicológica de Organocalcogênios, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria, CEP 97105-900, RS, Brazil.lld:pubmed
pubmed-article:19961893pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19961893pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed